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Breast cancer is the most frequent type of nonskin malignancy among women worldwide. In general, conventional cancer
treatment options (i.e., surgery, radiotherapy, chemotherapy, biological therapy, and hormone therapy) are not completely effective.
Recurrence and other pathologic situations are still an issue in breast cancer patients due to side effects, toxicity of drugs in normal
cells, and aggressive behaviour of the tumours. From this point of view, breast cancer therapy and adjuvant methods represent a
promising and challenging field for researchers. In the last few years, the use of some types of complementary medicines by women
with a history of breast cancer has significantly increased such as phytotherapeutic products and nutritional supplements. Despite
this, the use of such approaches in oncologic processes may be problematic and patient’s health risks can arise such as interference
with the efficacy of standard cancer treatment. The present review gives an overview of the most usual phytotherapeutic products
and nutritional supplements with application in breast cancer patients as adjuvant approach. Regardless of the contradictory
results of scientific evidence, we demonstrated the need to perform additional investigation, mainly well-designed clinical trials
in order to establish correlations and allow for further validated outcomes concerning the efficacy, safety, and clinical evidence-
based recommendation of these products.
1. Introduction
Breast cancer is a significant public health problem in both
developed and developing countries [1, 2]. Despite superior
diagnostic skills and valuable advances in its treatment during
the last decades, breast cancer persists in representing one
of the most commonly diagnosed occurring cancers and
leading cause of cancer deaths among women worldwide
[3]. According to World Health Organization (WHO) it is
estimated that worldwide over 508,000 women died in 2011
due to breast cancer [4]. The epidemiologic parameters (e.g.,
incidence, mortality, and survival rates) related to breast
cancer diverge significantly between countries and regions [1,
5] which could be attributed to various factors such as health
habits, lifestyle changes (e.g., dietary changes), exposure to
radiation, family history, related alterations in menstrual
cycle patterns, early detection, and access to the current
knowledge concerning breast cancer [3, 5].
The stage of diagnosis influences both the prognostic and
the treatment strategies for breast cancer. Currently, standard
treatment protocol combines a multidisciplinary approach
involving different therapies such as surgery, radiation, and
medical oncology (i.e., chemotherapy, immunotherapy, and
hormonal therapy) to obtain a local (i.e., remove or destroy
cancer in the breast) or systemic (i.e., destroy or control
cancer cells throughout the body) effect [3].
Despite the high incidence, breast cancer survivors,
which used Complementary and Alternative Medicines
(CAM), associated with standard cancer therapy, namely,
chemotherapy and radiotherapy, are increasing [6, 7]. The
use of CAM is growing among the public, up to 65% of the
European population uses this modality of medicine, and it is
commonly practiced among cancer patients [8]. Some studies
associated the increased CAM use with sociodemographic
issues such as female gender, higher levels of education,
higher income, and health insurance [9–12] that explains its
advance in many developed countries.
CAM is defined as a group of different modalities,
including diverse medical and healthcare systems, products,
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Figure 1: Components of integrative oncology (adapted from [16]).
and practices, which are not usually considered part of
standard medical treatments [13]. This type of medicine
could be used together with and thereby complement con-
ventional medicine which is referred to as complementary
medicine (e.g., using acupuncture to assist the side effects of
conventional cancer treatment) or in place of conventional
medicine (e.g., using a special diet to treat cancer instead of
a conventional cancer treatment) [13, 14]. Despite alternative
medicine being based on functional hypotheses often con-
flicting with conventional medicine, the complementary one
uses the scientific approach of evidence-based medicine to
support the conventional medicine. Currently an additional
and promising term is emerging in this area, the “integrative
medicine” which is based on the integration of conventional
and complementary approaches together in a coordinated
way that have been confirmed to be safe and effective [13,
15]. In CAM perspective, the patients are evaluated as a
whole with all their complexities and connections instead of
focusing on isolated pathological processes [15].
There are different classifications of CAM therapies which
vary mainly with time and institutional approaches. In
accordancewith theNational Centre for Complementary and
Integrative Health, a reference USA Federal Agency, CAM
therapies can be divided into three broad categories [13]:
(i) Natural products which include dietary supplements
(e.g., vitamins, minerals, and probiotics) and phy-
totherapeutic products.
(ii) Mind and body practices and manipulations which
include different procedures or techniques such as
yoga, chiropractic and osteopathic manipulation,
meditation, massage therapy, acupuncture, relaxation
techniques, tai chi, healing touch, qi gong, hypnother-
apy, and movement therapies.
(iii) Other complementary health approaches which
include some approaches that may not neatly fit into
either of the previous group, for example, traditional
healers, Ayurvedic Medicine, Traditional Chinese
Medicine, Homeopathy, and Naturopathy.
In the oncology field, the patient survival rates have
increased in recent years, so the practice of integrative
care, termed integrative oncology [16] (Figure 1), makes the
acceptance of the holistic approach to cancer care by medical
professionals feasible, onceCAMmodalities canmeet various
needs of the patients that go beyond the simple alleviation of
severe side effects of conventional cancer treatments.This fact
explains the use of CAM approaches by a great proportion
of cancer patients [17, 18] and, among these patients, women
with breast cancer remain the most likely users of some form
of CAM modalities [12, 19–21] with an estimated rate as
high as 75% [22]. Dobos et al. reported the practice of the
concept of integrative oncology for breast cancer patients by
German cancer centres such as the Department of Internal
and Integrative Medicine, Kliniken Essen-Mitte, academic
teaching hospital of the University of Duisburg-Essen, and
the Breast Centre at Kliniken Essen-Mitte [16].
The reasons reported by breast cancer patients for the
widespread use ofCAMdiverge and include [12, 19] activating
the immune system, curing cancer, alleviating symptoms
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associated with the side effects of conventional cancer treat-
ments, enhancing quality of life, increasing the perception
of disease control, and preventing relapse and prolonging
survival. Consequentially, the patients attempt to be active
and gain autonomy [23].
However, the use of certain CAM methods in oncologic
processes (i.e., a life-threatening disease) may become prob-
lematic and several partly substantial risks for the health
of patient can arise, particularly when, as commonly hap-
pening, patients use them arbitrarily and do not report this
information to their oncologists [19, 24–26]. This is true
mainly for CAM recommendations or treatments that inter-
fere/interact with chemotherapy or endocrine/hormonal
treatment approaches, such as phytotherapeutic products
and dietary supplements, or have intrinsic toxicity or other
negative effects. Despite such interactions possibly being
beneficial, in some situations, the concomitant use of CAM
and conventional medicines approaches could compromise
or be in conflict and enhance the drug toxicity or reduce the
effectiveness [27]. A well-known example is phytoestrogens
that might neutralize endocrine therapies. So, there are some
CAM modalities that require a temporary adjustment of
their use during periods of conventional treatment [28].
Additionally, among the CAM modalities, the consumer
of these natural products is the most popular in breast
cancer patients [19, 24] probably due to the assumption
that “natural” products are less toxic than conventional
prescribedmedicines [29].Therefore, attending the proactive
role that nowadays the patients have in relation to their
health, it is crucial to have reports in integrative medicine
to guide and support clinicians and patients. The aim is to
improve clinical/healthcare outcomes in combining CAM
and conventional care and prevent misuse of CAM methods
and preparations. The purpose is also to prevent harmful
interactions and to enrich personal control over disease.
Based on the intensive investigation of nutritional sup-
plements and phytochemicals as breast cancer therapeutics,
the aim of this study is to compile and to explore the
available scientific information regarding the most common
phytotherapeutic and nutritional supplement products used
in breast cancer patients.Therefore, recent scientific evidence
studies (e.g., systemic reviews and clinical investigation
studies) are consulted and the clinical relevant and validated
outcomes concerning efficacy, safety, and limitations of the
clinical data are reported.
2. Methodology
To elaborate this review, PubMed (indexed for MEDLINE)
and ISI Web of Science were searched using the follow-
ing key words: breast cancer; phytotherapy; supplements;
CAM; integrative medicine; Echinacea; Tabebuia impetigi-
nosa; Salvia; Uncaria; Allium sativum L., Linum usitatissi-
mum; Curcuma; Camellia sinensis; Ginseng; Cimicifuga race-
mosa; Viscum album; vitamins; antioxidants; vitamin A; 𝛽-
carotene; vitaminC; vitamin E; vitaminD; selenium, calcium;
B complex; omega 3. For plants, both Latin designations and
common trivial names were considered for search strategy.
Additionally, text books were explored and reference lists
frompertinent reviewswere scrutinized.The literature search
was confined to the period between 2000 to March of 2017.
Systematic reviews, meta-analyses, and in vivo and relevant
cell line studies were considered for this review.
3. Phytotherapy
Among CAM used in cancer patients, herbal preparations
or phytotherapy is the most commonly and the oldest used
group of treatment [30]. Most of time, patients use plant
products for self-medication. It uses products derived from
all or parts of plants and is a common practice in all civiliza-
tions around the world including Asia, Africa, Europe, and
America. Herbal preparations may have superior risk of
adverse effects and therapy interactions than other comple-
mentary therapies due to the potential active ingredients of
various plants. Despite this, phytotherapeutic products are
not tested with the scientific rigor required of conventional
drugs nor are controlled by any purity and potency certificate
[3].
The recognition of medicinal plants as effective and inex-
pensive sources of synthetic novel chemotherapeutic com-
pounds is increasing in the last decades andmany researchers
focus their research on this promising area [31]. In the cancer
domain, the biological effects of herbal medicinal products
could be diverse such as [7] defence from malignancy by
increasing detoxification or cleaning, modification of the
action of some hormones and enzymes, reduction in side
effects and complications of chemotherapy and radiotherapy,
and improvement of the function of the body’s immune
cells (i.e., stimulates the production of cytokines including
interleukin, interferon, tumour necrosis factor, and colony
stimulating factor).
The reasons for using phytotherapeutic products include
[3] to lessen symptoms of disease and to prevent disease
(e.g., garlic contains high levels of organosulfur compounds
that have been experimentally proven to prevent cancer in
animals [32]).
In a prospective study using an exploratory analysis,
the authors found that some evidence that phytotherapeutic
products use among long-term breast cancer survivors (for at
least 10 years) was associated with inferior survival rates and
a poorer physical component score [30]. The most frequent
phytotherapeutic products used among long-term (at least
10 years) breast cancer survivors who participated in this
studywere Echinacea, herbal teas, and ginkgo biloba. Authors
reported limitations in the study such as few deaths for
mortality analysis and lack of information on when phy-
totherapeutics use was initiated, duration, or application. In
another study, McLay et al. [33] reported that 38% of treated
breast cancer patients (in a total of 360 questionnaires) use
herbal preparations (Echinacea, pomegranate, peppermint,
chamomile, grapefruit, garlic, and ginseng) that have the
potential to interact with adjuvant endocrine therapies (e.g.,
tamoxifen, anastrozole, letrozole, and exemestane). Garlic,
gingko, and Echinacea were the most frequently phytother-
apeutic products among African Americans (Black Women’s
Health Study) [34].
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3.1. Echinacea. Echinacea, amember of the familyAsteraceae,
has a long history of medicinal use. It is endemic to eastern
and central North America and is also cultivated in Europe.
Three different species of Echinacea can be used as phytother-
apeutic products: Echinacea purpurea, Echinacea angustifolia,
and Echinacea pallida [3].
Some authors justified the potential use of Echinacea as
an anticancer agent based on its rich content in flavonoids
that act as an immune-stimulant by promoting the activity of
lymphocytes thus increasing phagocytosis and the activity of
natural killer cells and inducing interferon production [35].
Although studies indicated the use of Echinacea among
breast cancer patients [30, 33, 34], there are not many studies,
even in vitro, that demonstrated its effects in this type of
cancer. Driggins et al. verified that despite Echinacea pallida
decreasing the growth rate of BT-549 mammalian breast
cancer cells, its effect was significantly lower as compared to
Echinacea purpurea [36]. Huntimer and collaborators used
Echinacea angustifolia roots and evaluated their activity when
combined with doxorubicin (i.e., cytotoxic agent) in MCF-7
human breast cancer cell line [37]. This study showed that
different constituents of Echinacea could have a different
effect on MCF-7 cell proliferation and could interfere with
cells treated with anticancer drug, affecting cell proliferation
despite the presence of doxorubicin (i.e., counteracting the
cell-killing activity of doxorubicin). Based on this effect, the
authors suggest that herbal medicines need to be examined
more closely for interactions with other chemotherapeutic
agents. Echinacea induce cytochrome P450 3A4 isoenzyme
system both in vitro and in humans [38, 39].This enzyme sys-
tem participates in the metabolism of many chemotherapeu-
tic agents. Goey et al. demonstrated that the recommended
dose and schedule of a commercially available Echinacea pur-
purea extract (A. Vogel Echinaforce, Biohorma BV, Elburg,
Netherlands) did not interact with docetaxel pharmacoki-
netics and this combination can be used safely [40]. Among
other therapeutic indications, docetaxel is approved for the
treatment of locally advanced or metastatic breast cancer.
The benefits of the use of Echinacea to reduce unwanted
effects of radiotherapy (e.g., leukopenia) are unclear [41].
Therefore, more clinical evidence is important to support
or refute the recommendations for Echinacea in relation to
cancer management.
Even though Echinacea seems to be relatively safe, it may
cause liver damage or suppress the immune system if used
for a prolonged period without a break (i.e., more than 8
weeks) [42]. Therefore, a patient with liver disturbance or
taking drugs that potentially cause liver toxicity (e.g., some
chemotherapy agents) should avoid Echinacea use.
3.2. Lapacho. Lapacho tree or pau d’arco is the common
name of Tabebuia impetiginosa Martius ex DC species, the
family of Bignoniaceae. It is a tree indigenous to the Amazo-
nian rainforest and other regions of South America and Latin
America. Pau d’arco has been used in traditionalmedicine for
many centuries due to its different physiological effects such
as fungicide, antibacterial, antiviral, anti-inflammation, and
anticancer [43]. Above all, special attention has been given
to the antitumour activity of 𝛽-lapachone (i.e., a constituent
of lapacho) against many in vitro cancer cell lines, including
breast cancer [44, 45] due to its action on reinforcing the
immune system.
The clinical evidence of the health benefits of lapacho is
restricted to studies related to its potential anticancer effects
in phase I and II clinical trials [46]. However, this effect was
not borne out by clinical trials [43]. The Food and Drug
Administration (FDA) registered it as a dietary supplement
with the following recommendation “to alleviate conditions
and symptoms of cancer.”
Despite the underlying mechanism being under investi-
gation [47], the cytotoxic effects to some cancer cells, includ-
ing breast cancer cell lines, are confirmed [45, 48, 49]. 𝛽-
Lapachone also sensitizes the response of different cancer cell
lines to ionizing radiation [50, 51], interacting synergistically
with this conventional cancer therapy. Bey and collaborators
showed that the combination of 𝛽-lapachone and radiation
exert synergistic effects against human mammary epithelial
cells (HMEC 1585), in which 𝛽-lapachone sensitizes cells to
radiation by inhibiting DNA repair, and radiation sensitizes
cells to 𝛽-lapachone by increasing oxidoreductase enzyme,
which reduces 𝛽-lapachone to an unstable semiquinone level,
in tumour cells [51].
Concerning the toxicity issues of lapacho, limited data are
available and more clinical trials are required to evaluate the
toxicity of 𝛽-lapachone toward normal human tissue and to
establish the best dosage range [52]. Tabebuia impetiginosa
tea emerges as generally safe and has a FDA regulatory
classification of “generally recognized as safe” (GRAS) status.
Recently, Lemos et al. [53] demonstrated genotoxic effects in
rats at a comparatively high dose range. The most important
interaction of this botanical product refers to the interference
in the biological cycle of vitamin K [46]. It is also important
to attend the variable quality and composition of the herbal
products commercially available.
3.3. Salvia. Salvia is the largest and the most important
genus of the family Labiatae [89]. This genus includes wild
growing and cultivated medicinally valuable species (e.g.,
Salvia bracteata and Salvia rubifolia) as well as ornamentals.
Salvia species present a high diversity in their secondary
metabolites (e.g., flavonoids, diterpenoids, volatile oils, and
tannins) which justify the multiple pharmacological effects
reported in the literature [90].
In breast cancer, different species were investigated for
their in vitro antiproliferative activity. Abu-Dahab et al.
[90] demonstrated that the ethanol extract of three species,
namely, S. syriaca, S. fruticosa, and S. horminum, presented
selective antiproliferative activity against oestrogen receptor
(ER) positive breast cancer cell lines with minimum toxicity
against normal human periodontal fibroblasts. Based on
their safe and selective effects, the authors suggested the
use of these Salvia species as promising plant-originated
anticancer agents. Other species also showed promising
results. S. triloba and S. dominica ethanol extracts showed
antiproliferative effects on adenocarcinoma of breast cell
line (MCF7, oestrogen receptor-positive) and human ductal
breast epithelial tumour cell line (T47D) via proapoptotic
cytotoxic mechanisms [91]. S. miltiorrhiza (i.e., Danshen
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which is widely used in traditional Chinese medicine)
exhibited a strong inhibitory effect on the proliferation of
MCF-7 breast cell line and induced cell cycle delay in the
G1 phase via modulation of Akt phosphorylation and p27
level [92]. Authors also used MCF-7 HER2 cell line which
over expresses HER2. HER2 (i.e., human epidermal growth
factor receptor type 2) is a receptor tyrosine kinase and is
involved in signal transduction pathways leading to tumour
cell proliferation. HER2 is overexpressed in a high percentage
of breast cancer (25–30%) and its overexpression is associated
with aggressive tumours, a high rate ofmetastasis and relapse,
poor prognosis, and limitation in treatment (in most cases
it became resistant to endocrine therapy such as tamoxifen)
[93, 94]. The MCF-7 HER2 cells were more resistant to the
Danshen actions.
Danshen extracts contain diterpene quinone and phe-
nolic acid derivatives such as tanshinone (I, IIA, and IIB),
cryptotanshinone, isocryptotanshinone, miltirone, tanshinol
(I and II), and salviol [95]. These compounds are antioxidant
agents and protect against lipid peroxidation. Some of these
compounds have been isolated from Danshen, sometimes
synthesized, and their in vitro cytotoxic activity tested against
diverse cancer cell lines, including breast cancer [96–99].
Besides the in vitro inhibition of ER-positive human can-
cer cells lines, Wang and collaborators also proved that
neotanshinlactone was more potent and more selective than
tamoxifen citrate [96]. In this area, only one in vivo study
has reported anticancer activity on mice bearing human
breast infiltrating duct carcinoma orthotopically [95], where
the compound tanshinone II A strongly inhibited the in
vitro proliferation of ER-positive breast cancer cells and
inhibited in vivo growth of ER-negative breast cancer. The
inhibition of proliferation and apoptosis induction of cancer
cells through upregulation and downregulation of multiple
genes involved in cell cycle regulation, cell proliferation,
apoptosis, signal transduction, transcriptional regulation,
angiogenesis, invasive potential, and metastatic potential of
cancer cells could explain in part the anticancer effect of
this compound. Chemotherapy resistance is a significant
problem in breast cancer therapy. Cai et al. reported the
reversal mechanism of salvianolic acid A (i.e., a phenolic
active compound extract from Salvia miltiorrhiza) in human
breast cancer paclitaxel resistance cell line, facilitating the
sensitivity of chemotherapeutic agents [100]. In another
study, the authors demonstrated that tanshinone II A amelio-
rated hypoxia-induced chemotherapy resistance to doxoru-
bicin and epithelial-mesenchymal transition in breast cancer
cell lines via downregulation of hypoxia-induced factor 1𝛼
expression [101]. However, in vivo studies are required to
support these achievements.
Wong et al. performed a clinical trial and concluded that
the coadministration ofCoriolus versicolor (Yunzhi, 50mg/kg
body weight, 100% polysaccharopeptide) and Salvia miltior-
rhiza (Danshen, 20mg/Kg bodyweight) could be a promising
approach to improve immunological function in posttreat-
ment breast cancer patients [54]. Patients supplemented for
6 months presented significantly elevated values of absolute
counts of T-helper lymphocytes, the ratio of T-helper/T
suppressor and cytotoxic lymphocytes, and the percentage
and absolute counts of B-lymphocytes and decreased values
of plasma sIL-2R concentration. In other clinical study, the
intravenous administration of Salvia miltiorrhiza extract was
able to reduce ischemia and necrosis of skin flaps after
mastectomy as well as anisodamine administration but with
no adverse effects [55].
3.4. Uncaria. Two species of Uncaria, commonly known as
cat’s claw, Uncaria guianensis and Uncaria tomentosa, found
in northern regions of South America and belonging to
Rubiaceae family, have also promising medicinal outcomes,
including in breast cancer patients, due to their immune-
stimulant and antioxidant properties [102]. This botanical
product contains a complex combination of phytochemicals,
including glycosides, tannins, flavonoids, and sterol frac-
tions that could be complementary and/or synergic in their
pharmacological actions [3]. Some of these constituents can
present selectively cytostatic/cytotoxic to some cancer cells
such as pentacyclic oxindole alkaloids [103].
Although some studies revealed the in vitro efficacy of
cat’s claw in breast cell lines [102, 249] no clinical trials
investigating Uncaria species as an anticancer agent are
available. It is fundamental thatmore research is performed in
animal models andmainly in humans before any conclusions
can be drawn in this topic.
Utilising Uncaria tomentosa appears to be a benefi-
cial approach to minimize the adverse effects associated
with traditional cancer therapies, namely, in the case of
chemotherapy. The use of this Uncaria species can stimulate
DNA restoration [250], preventing mutations and cell dam-
age caused by chemotherapy agents [251], and myelopoiesis
[252, 253]. Aqueous extracts of U. tomentosa also proved to
improve leukocyte counts during a period of eight weeks
in healthy animals [254] and after ten days of doxorubicin-
induced neutropenia [251]. In addition, extracts or frac-
tions of cat’s claw modulate the activity of the immune
system [254, 255]. These preclinical data were proved in a
randomized clinical trial. Santos Araujo Mdo et al. used
300mg per day of U. tomentosa dried ethanolic extract, in
patients diagnosed with Invasive Ductal Carcinoma Stage
II, who underwent a treatment regimen known as FAC
(Fluorouracil, Doxorubicin, and Cyclophosphamide) [56].
This adjuvant treatment for breast cancer patients was safe
and effective in the recovery from neutropenia induced by
cancer chemotherapy. The dose used in this trial was empiric
and was based on the dose administrated in other (not
cancer-related) clinical trials where the authors used different
solvent extracts and, consequently, different phytochemicals.
So, more clinical trials should identify the best dosage range
for using cat’s claw as an adjuvant chemotherapy agent.
Buda´n et al. indicated that the combination of different
phytotherapeutic (e.g., Clae of Dragon tea containing the
bark ofUncaria guianensis,Uncaria tomentosa, and Tabebuia
avellanedae) in a long-term experimental animalmodel acted
as chemopreventive agent [256].
Concerning their safety, clinical trials with human vol-
unteers reported no toxicity associated with the use of
a commercially available aqueous extract of U. tomentosa
named C-Med-100. The dose of Uncaria was different in the
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trials, using 250mg or 350mg/day over 8 weeks and 2 ×
350mg daily for 2 months [250, 257].
Cat’s claw could provoke adverse effects including diar-
rhoea or loose stools and lower blood pressure, which tend
to diminish with continued usage. However, some litera-
ture reported that cat’s claw can interact with medications
intended to suppress the immune system (e.g., cyclosporine)
or other medications prescribed following an organ trans-
plant; this information still needs to be proven scientifically.
In vivo rat studies demonstrated that cat’s claw may protect
against gastrointestinal injury attributed to nonsteroidal anti-
inflammatory drugs (NSAIDs) and can diminish the platelet
aggregation and may increase the effect of anticoagulants
[103].
3.5. Allium sativum L. Allium sativum, commonly known
as garlic, presents different biologically useful secondary
metabolites with high sulphur content, such as S-allyl-
cysteine, diallyl disulphide, diallyl trisulfide, and methyl
allyl trisulfide [258]. Garlic also contains other beneficial
compounds such as arginine, oligosaccharides, flavonoids,
and selenium (i.e., cellular antioxidants) [259]. The main
active ingredients of garlic, organic sulphur compounds, have
attracted great attention as cancer prevention and treatment
agents in breast cancer [260–263]. Among these constituents
derived from garlic, the oil-soluble compounds are more
effective thanwater-soluble compounds in suppressing breast
cancer [264]. The mechanisms involved in the anticancer
effect of garlic-containing compounds include activation of
metabolizing enzymes that detoxify chemical carcinogens,
inhibition of DNA adduct formation, suppression of reac-
tive oxygen species production, induction of apoptosis, and
regulation of cell cycle progression and signal transduction
modification [264]. All referred to studies used experimen-
tal breast cancer cell lines, other studies extended their
anticancer evidences to in vivo models [265, 266], and no
clinical trials are available in literature. For example, Liu
et al. [260] demonstrated that diallyl trisulfide, a natural
organosulphuric compound with most sulphur atoms found
in garlic, suppressed the migration and invasion of breast
cancer cell lines (MDA-MB-231 cells and HS 578t cells)
and suggested that the inhibitory effects are associated with
downregulation of the transcriptional activities of nuclear
factor-kappa (NF-𝜅B, a transcription factor that regulates
the expression of antiapoptotic proteins) and ERK/MAPK
(i.e., major kinases involved in cell survival) signalling path-
ways. Inmanymalignant tumours, constitutiveNF-activation
occurs and consequently inflammation, proliferation, resis-
tant to apoptosis, invasion, and so forth [267]. These authors
reported that a concentration of diallyl trisulfide equal to
10 𝜇M should be achieved in vivo for preventing or treating
breast cancer. Chandra-Kuntal and collaborators established
the critical role for reactive oxygen species in the anticancer
effects of diallyl trisulfide compound using human breast
cancer cells (MCF-7 and MDA-MB-231). Using an oestrogen
receptor-negative human breast cancer cell line (MDA-MB-
231), Nakagawa et al. [266] reported that diallyl disulphide
synergizes the effect of eicosapentaenoic acid, a breast cancer
suppressor, and antagonizes the effect of linoleic acid, a
potent breast cancer stimulator. Diallyl trisulfide inhibits the
expression of ADAM10 and ADAM17 (proteases with a role
on metabolism of abnormal cells and whose high expression
is associated with a lower disease-free survival in breast
cancer patients) in estrogen-independent MDA-MB-231 and
estrogen-dependent MCF-7 breast cancer cells and seems to
promote growth inhibition of breast cancer cells [268].
In terms of the cancer prevention, Wargovich et al.
demonstrated robust chemopreventive action of constituents
of garlic against experimentally induced cancer, including the
mammary gland [32].
Despite garlic affecting cytochrome P450 3A4 activity,
Cox et al. showed that garlic supplementation does not
significantly affect the disposition of docetaxel but it can
decrease the clearance of docetaxel in patients carrying a
CYP3A5∗1A allele (present in all African American) [58].
A case-control study performed in northwest Iran aimed
to find the association between dietary Allium consumption
and risk of breast cancer. The study included 285 women
(25–65 years old) diagnosed with histopathologically con-
firmed breast cancer (grade II or III or clinical stage II or III)
which completed a food-frequency validated questionnaire.
A reduced risk of breast cancer associated with higher con-
sumption of garlic and leek and an increased risk associated
with high consumption of cooked onion was found [57].
No interactions are reported. Theoretically, garlic can
increase bleeding with anticoagulants, aspirin, and antiplate-
let drugs [269].
3.6. Linum usitatissimum. Linum usitatissimum (flaxseed)
is known for its phytoestrogen lignans content, namely,
secoisolariciresinol diglucoside, which are converted into
mammalian lignans (enterolactone and enterodiol) by bacte-
rial fermentation in the colon [270].This bacterial conversion
beneficially influences the anticancer effects of flaxseed [271].
Based on their structural similarity to estrogens, mammalian
lignan metabolites can attach to oestrogen receptors and
inhibit the growth of estrogen-stimulated breast cancer
[3]. Flaxseed can modulate the estrogen metabolism and
oestrogen receptor and epidermal growth factor receptor
signalling pathways [272]. Flaxseed also contains up to 40%
oil which is mainly rich in 𝛼-linolenic acid-rich oil (i.e., 𝑛-3
polyunsaturated fatty acid).
However, some questions remain and are discussed, such
as if flaxseed and its compounds are effective in reducing the
breast cancer risk, present antiproliferative properties, and
can interact beneficially with conventional cancer therapy.
In 2013, a Canadian study revealed that flaxseed intake
alone is associated with a prevention of breast cancer [59].
In vitro studies showed that flaxseed induces apoptosis
and inhibits human breast cancer cells proliferation [273–
276]. Animal models have shown that flaxseed, secoiso-
lariciresinol diglucoside, and flaxseed oil can reduce the
growth of breast cancer [277–279]. Additionally, experimen-
tal studies using rodents demonstrated that flaxseed dietary
inclusion has antiproliferative effect in different heterotrans-
planted mammary carcinomas in mice [280–282]. For exam-
ple, Chen et al. proved that flaxseed diet on a mouse model
has a dose-dependent inhibition of breast tumour growth
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[283]. In addition, flaxseed also contributed to decreased
metastasis and tumour angiogenesis [60, 279, 284].
Even though numerous experimental studies using ani-
mal models being available in literature, there are a few stud-
ies concerning the influence of flaxseed on breast carcinomas
in humans and more clinical trials are required to assess
whether flaxseed has anticancer properties in humans. No
study reveals that flaxseed has a negative effect. For example,
in a double-blinded, randomized controlled clinical trial, the
dietary flaxseed demonstrated remarkable protection with
a reduction in tumour growth and alteration of tumour
biological markers in postmenopausal breast cancer patients
[285]. Buck and collaborators [63, 286] also reported the
beneficial effect of flaxseed ingestion and high serum lignan
levels in the survival rate of postmenopausal patients with
breast cancer.
Taking into consideration the interaction of flaxseed
in chemotherapy, Chen et al. demonstrated that 𝑛-3 fatty
acid-rich cotyledon fraction of flaxseed reduced the growth
of ER-positive human breast tumours, alone and in com-
bination with tamoxifen, increasing the effectiveness of
this chemotherapeutic agent [280]. Some studies reported
the decreased tumour angiogenesis with the association
of flaxseed and tamoxifen [60, 61] and the tumour cell
apoptosis with flaxseed and doxorubicin [287]. In a recent
study, Manson et al. reported that dietary flaxseed pre-
sented minimal tumour-reducing outcome did not interfere
with trastuzumab action (a recombinant humanized mon-
oclonal antibody used as the first-line therapy in HER2-
overexpression breast cancer) but enhanced survival in
athymic mice with established HER2-overexpressing human
breast tumours [288]. However, the use of flaxseed oil com-
bined with trastuzumab increased the effectiveness of low
doses of this monoclonal antibody, that is, reduced tumour
size and cell proliferation and increased apoptosis on HER2-
overexpressing breast tumours (BT-474) in athymic mice
compared to trastuzumab alone [289]. The author suggests
the potential use of flaxseed oil as a complementary treat-
ment for premenopausal women undergoing trastuzumab
treatment, reducing the dose, and, therefore, lowering the
side effects andpotentially increasing survival rates.However,
these recommendations should be confirmed through clini-
cal trials. The use of flaxseed and aromatase inhibitor (using
anastrozole as model drug) was also studied by MaCann and
collaborators using biopsy and resection samples from post-
menopausal women with oestrogen receptor-positive breast
cancer [62]. Nevertheless, the results did not support strong
effects on aromatase inhibitor activity but suggested that
anastrozole might reduce the beneficial effects of flaxseed.
Additionally, Chen et al. verified that flaxseed com-
ponents (secoisolariciresinol diglucoside and oil) did not
attenuate the positive effects on bone health induced by
tamoxifen (i.e., increase bone mineral content and density)
in breast cancer patients [290].
Based on the current evidence, the flaxseed and its
components are safe and effective in reduction risk and
treatment of breast cancer. Despite this, the use of flaxseed is
associated with bowel obstruction and bleeding disorder [3].
3.7. Curcuma longa. Turmeric plant (Curcuma longa) is
widely used in food as a dietary spice and in traditional
medicine as a remedy for different diseases including dia-
betes and hepatic disturbances [291]. Curcumin, the active
compound of turmeric, has antioxidant effects and has been
demonstrated to be a promising agent in clinical oncology
due to its chemopreventive, antiproliferative, and apoptosis
effects [292].
Curcumin can modulate multiple biological pathways
involved in mutagenesis, oncogene expression, cell cycle
regulation, apoptosis, angiogenesis, tumour genesis, and
metastasis, which could justify its anticancer outcome [293].
Various preclinical studies focused on the anticancer
efficacy of curcumin have been tested in some cancer models
including breast cancer. The inhibition effect of curcumin
alone, in combination with chemotherapeutic agents, on in
vitro human breast cancer cells lines has been proved [294–
299]. The same effects have also been observed in animal
models. Zhan and collaborators [296] demonstrated the
increased antitumour efficacy on mouse models of combin-
ing paclitaxel with curcumin and suggested the promising
therapeutic potential and underlying mechanisms of this
therapeutic association in breast cancer treatment. Ferreira
et al. reported the effectiveness in reducing tumour growth
and cell proliferation as well as in the suppression of angio-
genesis using intraperitoneally curcumin administration in
a xenograft model of breast cancer [300]. Research studies
referred to different molecular mechanisms underlying the
antitumour activity of curcumin in breast cancer cells, such
as modulating the NF-B signalling pathway [296, 297, 301–
303], decreasingHER2 oncoprotein expression, the phospho-
rylation of Akt, MAPK, the expression of NF-B in both BT-
474 and SK-BR-3-HR cell (i.e., a herceptin resistant strain
from SK-BR-3) [304], and the induced apoptosis by inhibit-
ing fatty acid synthase [305]. Additionally, some authors
found that curcumin suppressed breast tumour angiogenesis
through abrogating osteopontin or medroxyprogesterone
acetate induced VEGF expression [306, 307]. Soung and
Chung showed that the association of epigallocatechin gallate
and curcumin has an efficacy outcome in both in vitro and
in vivo models of ER𝛼-breast cancer by the regulation of
epidermal growth factor receptor expression [308].
Curcumin is a lipid-soluble compound with limited bio-
availability and extensive metabolization. Some researchers
used different technological strategies to sustain the delivery
of curcumin and overcome the intrinsically poor bioavail-
ability, such as nanotechnology and liposomal-based formu-
lations and synthetic analogues of curcumin [309–313]. The
results from these studies demonstrated promising outcomes
for clinical transposition.
Most of the clinical trials that evaluated the curcumin
used in cancer treatment refer to colorectal and pancreatic
cancers. Bayet-Robert et al. [64] performed a clinical phase
I dose escalation trial of combination docetaxel chemother-
apy with curcumin in advanced and metastatic breast can-
cer patients. The authors confirmed the safety profile of
this combination therapy which was consistent with that
observed with a monotherapy of docetaxel. Additionally,
curcumin/docetaxel combination proved antitumour activity
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and a superior response rate in comparison to docetaxel
in monotherapy. The recommended dose of curcumin is
6.0 g/day for seven consecutive days every 3 weeks in com-
bination with a standard dose of docetaxel which proved its
feasibility, safety, and tolerability. However, some scientific
evidence demonstrated that dietary curcumin can inhibit
chemotherapy-induced apoptosis in models of human breast
cancer lines (MCF-7, MDA-MB-231, and BT-474) [314].
The chemotherapeutic agents evaluated were camptothecin,
mechlorethamine, and doxorubicin-induced apoptosis. In
conclusion, additional clinical studies are required to demon-
strate the avoidance of curcumin (in both supplements and
intake foods containing curcuma) in breast cancer patients
undergoing chemotherapy.
In addition, this phytotherapeutic agent is well tolerated
in human subjects. Therefore, curcumin could be considered
an alternative nontoxic agent in the treatment of one of
the most aggressive breast cancer, that is, triple negative
breast cancer (ER-negative, PR-negative, and HER2/neu not
over expressed) [303]. This breast cancer remains the most
challenging factor in cancer treatment.
3.8. Green Tea. Green tea extract is prepared from the
steamed and dried leaves of Camellia sinensis and con-
tains flavonoids, a large group of polyphenolic com-
pounds with antioxidants properties [269]. Epigallocatechin-
3-gallate (EGCG) is the most abundant polyphenol in green
tea and has been the focus of preclinical and clinical research
on health beneficial effects [3]. However, the main mecha-
nism by which green tea might help to prevent cancer has not
been recognized.
In vitro and animal studies demonstrated that tea
polyphenols can inhibit tumour cell proliferation and induce
apoptosis [315, 316]. Additionally, tea catechins have revealed
the ability to inhibit angiogenesis and tumour cell invasive-
ness as well as modulate the immune system function [317].
The chemopreventive potential of green tea contrasts with
the consistent results from animal models. Evidence of green
tea consumption on breast cancer prevention and develop-
ment is not supported by epidemiologic studies and the role
of green tea consumption in breast cancer remains unclear.
The results of antiproliferative effect of green tea extracts or its
polyphenols fromhuman studies are inconsistent and depend
on the type of cancer [318]. A systematic review and meta-
analysis of prospective observational studies, 57 relevant arti-
cles, concluded that tea consumption has no significant effect
on the risk of common malignancies including breast cancer
[65]. A prospective cohort study performed in Japan found
no association between green tea drinking and risk of breast
cancer [66]. However, in a case-control study conducted by
Zhang and colleagues in Southeast Chine between 2004 and
2005, despite the fact that the authors concluded that regular
consumption of green tea can protect against breast cancer,
they also suggested more research to closely examine the
relationship between tea consumption and breast cancer risk
[67].
In a follow-up study, despite prevention recurrence
of stage I and II breast cancer being observed with an
increase green tea intake, no improvements were confirmed
in patients with stage III breast cancer. A potential prevention
of green tea consumption in breast cancer recurrence in early-
stage (I and II) cancer was also reported by Seely et al. [77].
In order to better evaluate the in vivo exposure to
specific tea catechins, two studies incorporated prediagnostic
biomarkers of green tea intake and metabolism on risk of
breast cancer [68, 69]. In a prospective cohort in China,
urinary tea catechins and their metabolites were measured
in 353 cases and 701 controls and no association was found
between urinary concentrations of biomarkers measured and
risk of breast cancer [69]. Similar results were achieved in
a prospective cohort Japanese study in which tea catechins
biomarkers concentrations were measured in plasma [68]. In
both studies, the detectable rates of some biomarkers were as
low as 20–30%, which increased concern about the sensitivity
of the assays, because ∼50% of study participants reported
drinking at least one cup of green tea daily. Crew et al.
conducted a study using archived blood/urine from a phase
IB randomized, placebo-controlled dose escalation trial of an
oral green tea extract, polyphenon E (Poly E), in breast cancer
patients [70]. The results suggested that the consumption
of EGCG can have a preventive effect in breast cancer by
influencing the growth factor signalling, angiogenesis, and
lipid metabolism mechanisms.
In a cross-sectional study, including 3315 Asian women,
daily green tea consumption demonstrated a significantly
lower mammographic density percentage compared to
nontea drinkers [319]. Mammographic density is a well-
established breast cancer risk factor. The difference in
mammographic density was observed mainly among post-
menopausal women. The authors suggest that long-term
exposure to green tea may act as a protective approach in
breast cancer.
In addition, genetic factors may have an important role
in the influence of green tea on breast cancer, namely,
genetic polymorphism in angiotensin-converting enzyme
gene and in the catechol-O-methyltransferase gene, probably
due to the interindividual differences in the metabolism and
elimination of tea polyphenols [71, 72]. In the specific case of
catechol-O-methyltransferase gene, studies have inconsistent
findings. Wu et al. [73] conducted a population-based case-
control study in Asians in Los Angeles County and reported
that consumption of green tea was associated with significant
reduced risk of breast cancer in women carrying at least
one copy of the low-activity catechol-O-methyltransferase
allele relative to nondrinkers. In women carrying both high-
activity catechol-O-methyltransferase alleles no association
was found. In the Chinese population, the catechol-O-
methyltransferase genotype did not present any modifying
effect on the association between tea consumption and breast
cancer risk.
Green tea has also demonstrated a promising role as
adjuvant of chemo/radiotherapy due to both additive or
synergistic effects and amelioration of cancer therapy side
effects [320]. However, further clinical research is required to
ascertain the effectiveness of these actions. EGCG canmodify
the pharmacokinetics of tamoxifen and induce chemosen-
sitization in tamoxifen-resistant breast cancer cells [321].
In another study, the cotreatment of EGCG and tamoxifen
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increased apoptosis and reduced tumour growth in breast
cancer cells using a murine model of breast carcinoma,
enhancing the cytotoxicity of paclitaxel [322]. EGCG also
has antiproliferation activity against estrogen-induced breast
cancer cells (e.g., sunitinib) [323] and sensitives hormone
responsive tumours to drugs that act in steroid receptors (e.g.,
tamoxifen) [321, 324]. Li et al. reported chemosensitization
and synergistic anticancer effects with the coadministration
of EGCG and histone deacetylase inhibitor trichostatin A in
oestrogen receptor-negative breast cancer cells [325]. Zhang
et al. conducted a clinical trial in breast cancer patients
undergoing radiotherapy and supplemented with EGCG.
The results showed that EGCG and its metabolites could
potentiate the effects of radiotherapy [74]. Green tea also
seems to protect the body against the harmful effects of
radiation and chemotherapy [7, 320].
In the Minnesota Green Tea Trial, 1075 postmenopausal
women at high risk of breast cancer due to dense breast tissue
randomly consumed green tea extract (845mg EGCG) or
placebo, daily for one year. The safety of green tea was also
tested. The main conclusion was that there were no statis-
tically significant differences between groups in frequencies
adverse events or serious adverse events, but EGCG con-
sumption leads to a higher incidence of nausea, dermatologic
events, and alanine aminotransferase elevation [75].
Lazzeroni et al. [76] studied the EGCG tissue distribution
and evaluated its effect on cell proliferation in breast cancer
patients. The consumption of 300 g of tea catechin extract
phytosomes (equivalent to 44.9mg of EGCG) increased the
bioavailability of EGCG, which was detectable in breast
tumour tissue and is associated with a decrease in the tumour
circulating biomarker revealing antiproliferative effects on
breast cancer tissue.
Based on the current data, large randomized intervention
trials focusing on the efficacy of green tea polyphenols
are required before a recommendation as preventive-cancer
should be made.
No known contradictions are reported. Green tea has
been consumed safely over thousands of years; recently a liver
toxicity has been reported. However, this is probably related
to the presence of contaminants in the plant.
3.9. Ginseng. The generic term ginseng encloses several
species of plants belonging to the genus Panax such as
Panax ginseng and Panax japonicus (i.e., Asian ginseng) and
Panax quinquefolius L. (American ginseng) [269]. In recent
years, ginseng has gained popularity in Western countries
and is included in the Pharmacopoeias of Germany, Austria,
and United Kingdom [326]; in the United States, ginseng
is the second top-selling herbal supplement but it is not
a drug approved by the Food and Drug Administration
[327–329]. Ginseng presents a complex mixture of various
active compounds but the main pharmacologically active
ingredients are triterpene saponins known as ginsenosides,
which are found in the roots. Therefore, the dried roots are
used in traditional medicines due to the variety of beneficial
effects, including in breast cancer [330, 331]. However, its
clinical significance in breast cancer patients has not been
fully investigated and some divergences are reported.
Despite several in vitro studies having proved the promis-
ing use of ginseng extract or its active components as
anticancer agent in breast cancer [332, 333], no animal
studies have been found in literature. The mechanisms by
which components of ginseng ormetabolites performed their
antiproliferative effect are reported in several research studies
and resumed in a recent review paper [334]. These com-
pounds can modulate signalling pathways associated with
inflammation, oxidative stress, angiogenesis, metastasis, and
stem/progenitor-like properties of cancer cells. For example,
ginsenoside Rp 1 inhibits the insulin-like growth factor 1
receptor (IGF-1R)/Akt pathway in breast cancer cells [332].
In addition, ginsenoside Rp 1 was also demonstrated to
induce cycle arrest and apoptosis. Kwak et al. studied the
inhibitory effect of ginseng sapogenins and their derivatives
on the proliferation of MDA-MB-231 human breast cancer
cells (a model of triple negative breast cancer) [333]. 20(S)-
Protopanaxadiol exhibited IC50 (i.e., half maximal inhibitory
concentration) comparable to the taxol (chemotherapeutic
agent) and acts by stimulating caspase-dependent apoptosis
in breast cancer cells. The ability of ginsenoside Rg 3, one of
the major active compounds of heat-processed ginseng, to
induce apoptosis in MDA-MB 231 cells by blocking NF- B
signalling was also verified [335, 336].
A specific effect of ginseng in cancer is increasing the sen-
sitivity of breast cancer cells to various chemical anticancer
agents including gemcitabine (an antimetabolite), cisplatin
(an alkylating agent), paclitaxel (a taxane agent belonging
to a plant alkaloid), and epirubicin (an antibiotics) through
downregulation of them RNA level of MDR-1 [337].
Despite popular use of ginseng in cancer patients, only
a few clinical studies have been conducted on ginseng-
chemotherapeutic agent association. A clinical phase II study
using no ginseng alone but in Shengmai formula (i.e., a
traditional Chinese ginseng preparation that contains red
ginseng, lilyturf root, and magnolia vine fruit) reported
immunologic improvements among breast cancer patients
[78].
Some beneficial effects related to the use of ginseng in
human include maintenance of natural energy, improve-
ments of physical, chemical, and biological performance
and enhancement mood and general vitality and immune
function [326, 338]. Despite these positive outcomes which
are attributed to its “adaptogen” characteristic, findings on
the effects of ginseng in breast cancer patients are mixed. Bao
et al. [79] conducted the Shanghai Breast Cancer Survival
Study to detect some association between quality of life and
postdiagnosis ginseng use among breast cancer survivors.
The authors did not find any improvements. In another study,
Cui and collaborators reported that the use of ginseng had
positive quality of life scores, namely, in the psychological
and social domains [80].The authors explained the variability
in response to the design of study and the different doses of
ginseng use among breast cancer survivors.
Nevertheless, evidence of efficacy is sparse.Well-designed
clinical trials are required to provide information for scien-
tists and healthcare consumers. Furthermore, treatment of
symptoms and side effects is crucial for people with cancer
because of the longevity associated with successful cancer
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treatment. And regarding this issue, evidence is also required
in relation to ginseng use.
Ginseng should be avoided by children and used with
some prudence by patients medicated with blood pres-
sure medicines, blood-thinning medications, hormones, or
insulin due to possible drug-herb interactions (recommen-
dation performed by American Cancer Society) [3]. Ginseng
is relatively nontoxic but in high doses (i.e., superior to 3
g ginseng root daily) can confer adverse symptoms such as
insomnia, nervous excitation, headaches, and nausea. Gin-
seng may present steroid/hormone like effects, so in women
who have breast or endometrial cancer special attention to its
use is recommended [7, 339].
3.10. Black Cohosh. Black cohosh, also known as Cimicifuga
racemosa or Actaea racemosa (family of Ranunculaceae),
is a popular phytotherapeutic product frequently used for
women’s health concerns such as premenstrual syndrome,
dysmenorrhoea, and menopausal symptoms [3, 340]. A
recent meta-analysis of nine controlled placebo clinical trial
confirmed the efficacy of its use in relieving menopausal
symptoms [341].
This plant is included in the famous patent medicine
Lydia Pinkham’s Vegetable Compound and was listed in the
19th century Pharmacopoeia [342]. Black cohosh contains
unidentified substances with selective oestrogen receptor
modulator properties; however, triterpenes glycosides have
been assumed to be the crucial constituents for its biological
effects [342].
Few in vitro tests using breast cancer cell lines in
culture and in vivo animal studies evaluating the effect of
black cohosh as chemopreventive or anticancer agents are
reported in literature. Several components extracted from
black cohosh were tested in human breast cancer cells
revealing anticancer properties: cycloartane triterpenoids
induced mitochondrial apoptosis and cell cycle arrest, via
Raf/MEK/ERK signalling pathway and Akt phosphorylation
[343] or via NF-𝜅B signalling pathway [344]. Actein revealed
an antiangiogenic effect by inhibiting the proliferation and
reduced the migration and motility of endothelial cells (in
vitro). Oral administration of actein at 10mg/kg for 7 days
inhibited blood vessel formation and oral actein treatments
(10–15mg/kg) for 28 days resulted in decreasing mouse
4T1 breast tumour sizes and metastasis to lungs and liver
[345]. Nevertheless, some contradictory conclusions have
been indicated. For example, Einbond et al. conjugated a
triterpene glycoside of black cohosh and actein to liposomes
[346]. This vehicle increased the growth inhibition activity
of actein against human breast cancer cells. Actein presented
antiproliferative action bymodulation of theNF-BandMEK
pathways. Using female Sprague-Dawley rats, Weissenstein
and colleagues indicated that black cohosh could be chemo-
preventive or chemotherapeutic agents for mammary cancer
due to its immunohistochemistry effect [347]. However,
Davis and collaborators suggested that black cohosh may
increase metastatic mammary cancer in MMTV-neu mouse
model which is used due to its similarities to HER2(+) breast
cancer [348].
Black cohosh is one of themost controversial natural ther-
apies used among breast cancer patients due to its ambiguous
estrogenic or antiestrogenic activities with many studies
in literature exploring considerable debate over the safety
of its uses [349]. Under conditions of excessive estrogen,
the active ingredients of this plant may behave as estrogen
antagonists by a mechanism of competitive inhibition of
the ER. However, in the presence of low estrogen, actives
may act as weak agonists [350–352]. If black cohosh exhibits
estrogenic activity, it may result in potentially negative out-
comes on breast cancer risk or recurrence, mainly in women
undergoing antiestrogen therapy [353]. However, Fritz and
collaborators carried out a systematic review about the use
of black cohosh in breast cancer and found that evidence is
conflicting in all analysed aspects [81].The authors concluded
that current evidence does not sustain an association between
black cohosh and increased risk of breast cancer (results from
observational studies) and reduce evidence that supports
the efficacy of black cohosh for reduction of hot flashes in
breast cancer patients (results from observational studies and
clinical trials). Some limitations of studies include subjective
outcomes, different risk of bias, namely, lack of blinding
and inadequate reporting of withdrawals (for clinical trials);
variation of dose and duration schedules of black cohosh,
different products and methods of extraction, and lack of
information and criteria included in the retrospective design
(for observational studies). In addition, black cohosh seems
to have limited and no classic estrogenic activity as seen by its
effect on bone metabolism.
Different conclusions have also been reported concerning
the potential for interactions with antiproliferative effects of
different classes of chemotherapy agents. A cohort study sug-
gested that taking black cohosh can reduce risk of recurrence
in patients taking tamoxifen [82]. No risk of recurrent and no
consistent serious adverse events related to the combination
of black cohosh and tamoxifen were reported in clinical
trials [354, 355]. No interaction on the formestane- (i.e.,
an aromatase inhibitor-) induced tumour reduction was
observed with the coadministration of black cohosh extract
in a chemically induced rat model for mammary carcinoma
[356]. In humans, different findings were reported [357, 358].
The Clinical Practice Guideline of the Canadian Society
of Obstetricians and Gynaecologists list black cohosh inter-
actions with some drugs including anesthetics, antihyperten-
sives, and sedatives [359]. Despite this, Walji et al. conducted
a systematic review and suggested that black cohosh has a
high safety profile in cancer patients; however, the authors
did not include recent evidence [360]. In another study based
on animal studies, Freudenstein and colleagues suggested
that Cimicifuga racemosa extract is safe for treatment of
menopausal symptoms in breast cancer survivors in whom
hormone-replacement therapy is contraindicated [361]. Case
reports of hepatotoxicity have been reported but confounding
factors such as “poor case data quality, uncertain of black
cohosh product, quality, and insufficient adverse event def-
inition” could justify this adverse effect [362].
The outcome of black cohosh uses in women with or
without a history of breast cancer is unclear and its use must
be discouraged.
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3.11. Mistletoe. Mistletoe (Viscum album from the Viscaceae
family), as part of anthroposophical medicine, is potentially
effective against cancer and is used frequently in breast cancer
due to its minimal side effects and the fact that these side
effects are not life threatening [363]. The mistletoe contains
different types of biological active ingredients, but the main
constituents responsible for anticancer and immunomodula-
tory effects are lectins (ML-I, ML-II, and ML-III) [364, 365].
Experiments in cell cultures, animal models, and clinical
data propose that cytotoxic and antitumour activities of
mistletoe may be mediated by different mechanisms: apop-
tosis induction and necrosis, cell cycle inhibition [366, 367],
and activation of specific and nonspecific immune system
[368, 369].
Different in vitro studies demonstrated the antiprolif-
erative effect of mistletoe extract against breast cancer cell
lines [370, 371]. Kelter et al. proved that mistletoe extracts
have cytotoxic activity on different human breast cancer cell
lines and suggested that no growth stimulation of these cell
occurred [370]. Using human breast carcinoma cell lines
HCC 1937 and HCC 1143, Weissenstein and collaborators
suggested that no herb-drug interactions occurred from the
exposition of cancer cells simultaneously with doxorubicin
(i.e., a chemotherapeutic) and Viscum album extract [371].
Additionally, at higher concentrations of mistletoe extract
an additive in vitro inhibitory effect was observed. When
Viscum album extract was associated with trastuzumab in an
in vitro SK-BR-3 cells test, the results suggested no herb-drug
interaction and exhibited a complementary anticancer effect
[347]. A similar synergistic anticancer effect was observed
in inhibition in the growth of both breast cancer cell lines
(i.e., MCF-7—oestrogen receptor-positive—and MDA-MB
231-oestrogen receptor-negative) when the authors combined
doxorubicin and lectin fromKoreanmistletoe [372]. Further-
more, in vivo investigations using different animal models
were also presented in literature. For example, Beuth et al.
reported the dose-dependent anticancer activity of mistletoe
using a BALB/cmouse/BT474 ductal breast carcinomamodel
[373].
Several studies on breast cancer patients receiving
chemotherapy report an efficacy on survival rate, tumour
reduction and remission, and better quality of life with reduc-
tion of adverse reaction of standard chemotherapy when
additionally treated with mistletoe products [84–87]. Safety
and efficacy were set as the endpoints in a multicentric and
comparative clinical trial conducted by Beuth et al. among
women with primary breast cancer who received mistletoe
extract [88]. In clinical trials, some limitations should also
be pointed out such as limited sample size, lack of control,
exclusion and inclusion criteria of the clinical trial, quality
rating, and mistletoe preparations.
Twelve patients were selected by the presence of histo-
logical confirmed breast cancer tumour (≥2 cm in diameter)
and included in a study to investigate the mistletoe effect
in tumour regression of breast cancer. After six months, the
mistletoe extract therapy demonstrated being highly effective
[83].
Despite the promising results for the use of mistletoe in
addition to chemotherapy, the discussion on the reduction of
side effects and improvement of quality of life in breast cancer
patients remains open and is still a controversial topic.
4. Nutritional Supplements
In cancer topic, three different phases could be passive
of intervention with nutritional supplements: prevention,
during conventional treatments after diagnosis and survival
period.
Although studies have not established a specific role for
vitamins and selenium in the prevention of breast cancer,
some anticancer activities have been demonstrated using
tumour cell lines (i.e., in vitro) [374–376].
Some notable institutions in cancer research, such as the
American Cancer Society, the World Cancer Research Fund,
and American Institute for Cancer Research, advise against
the use of nutritional supplements for cancer survivors [377,
378]. Nevertheless, the supplementation with multivitamins
andminerals is frequent after a breast cancer diagnosis and in
survivors who recognize them as anticancer and antioxidant
agents [26, 34, 113, 379]. Despite this, the evidence base
for nutritional supplementation in cancer patients during
treatment remains inconsistent and ambiguous and the
results obtained in some studies have been contradictory.
For example, some observational studies performed in breast
patients have not reported improvements in breast cancer
prognostic [152, 380]; others showed beneficial effects [112,
123, 381] and some showed harmful events [123].
The information obtained with the studies that examine
the association between supplementation use and cancer-
related outcomes must be interpreted with care due to the
methodological limitations ofmost study designs such as lack
of complete prospective data on supplement uses, specifically
around the time of prediagnosis, diagnosis, and treatment
and lack of data collection on changes in supplement use over
time. Greenlee et al. [379] published a prospective cohort
study (the Pathways study) with methodological improve-
ments over previous studies in which the authors provided
specific detailed information on changes in supplementation
use following diagnosis in a multiethnic population. In
this study, most women used vitamin/mineral supplements
before (84%) and after (82%) diagnosis. The most commonly
initiated supplements were calcium and vitamin D; the most
commonly discontinued supplements were multivitamins,
vitamin C and vitamin E. In another study, the Intergroup
Phase III Breast Cancer Chemotherapy trial (S0221), the
authors collected data between 2003 and 2010 and reported
that 48%of patientswere takingmultivitamins; 20%were tak-
ing vitamins C and D and omega 3 fatty acids in fish oils; 15%
were taking vitamins E and B6 and folic acid; and 34% were
taking calcium. In this study, the advice of clinicians related
to the nutritional supplementation was diverse [382]. This
review refers only to the most commonly used nutritional
supplements among the breast cancer patients.
After reviewing the available scientific literature [157],
at this moment no consensual recommendation for cancer
patients is available even among the clinicians and a greater
understanding of processes involved in the regulation of
tumour growth is desirable.
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4.1. Multivitamins. Generally, cancer patients have an aug-
mented requirement for essential nutrients (e.g., vitamins,
trace elements, and minerals) adequate levels of which are
achieved with the supplementation products. This is partic-
ularly true before or during cancer destructive therapies for
supporting their side effects better.
However, multivitamin supplements are usually a hetero-
geneous group of products with no standard composition
that depends on the manufacturer, year of production, and
batches [104, 106]. In the Swedish Mammography prospec-
tive cohort study, Larsson and collaborators highlighted an
increase in the risk of developing breast cancer both for high
frequency of consumption (19%) and for long duration of
multivitamin supplementation (22%) [105].
Until now, no randomized trials have evaluated the
outcomes of multivitamin supplementation on the toxicity or
survival rate after breast cancer diagnostic [383]. However,
Kwan and collaborators conducted an observational study in
which 72% of womenwith early-stage breast cancer were self-
prescribing multivitamins and reported neither beneficial
nor harmful effects of these supplements on toxicity or
survival [113]. Similar conclusionswere foundbyWassertheil-
Smoller and collaborators in US postmenopausal women
with invasive breast cancer [111]. However, other authors did
not find any association of consumption ofmultivitamins and
breast cancer risk [106, 107].
4.2. Antioxidant Vitamins and Minerals. There is scientific
documentation that relates the high intake of antioxidant
with both a lower risk of developing breast cancer [104, 110]
and a positive impact in the mortality rates of cancer. In
accordance with the American Cancer Society and Cancer
ResearchUK, although the studies of nutritional supplements
to reduce cancer risk have not all been disappointing, until
now there is no consistent evidence that any type of nutri-
tional supplement can help to prevent cancer, in contrast with
the nutrients (including antioxidant) obtained in a healthy
and balanced diet with abundance of fruits and vegetables
[108, 384, 385]. Therefore, according to the American Cancer
Society, the best advice is to get antioxidants through food
sources rather than supplements.
The use of antioxidant agents in patients with can-
cer seems to be an intelligent idea based on their bio-
logic mechanism, first because of their potential anti-
cancer properties—that is, diminished oxidative damage;
reduced proliferation and angiogenesis; increased apoptosis
[386]—and second because they may reduce the oxida-
tive damage from conventional cancer treatments involving
chemo- and radiotherapy and therefore limited the toxicity
of these therapies [383].
Despite the potential improvement outcomes, the supple-
mentation with antioxidant agents (e.g., vitamin A, vitamin
E, vitamin C, and selenium) during cancer treatment is
discussed controversially mainly due to the probable inter-
action with or modification in the effects of conventional
cancer treatments [386, 387]. Since radiotherapy and sev-
eral chemotherapy agents (e.g., alkylating agents, anthra-
cyclines, podophyllin derivatives, platinum complexes, and
camptothecins) exert their anticancer properties through
production of reactive oxygen species (ROS) and promoting
apoptosis, the antioxidant agents may reduce the efficacy
of radio- and chemotherapy-related cytotoxicity and con-
sequently act as potential cancer-promoting. Antioxidant
supplements appear to successfully block otherwise effective
prooxidant therapies and protect both normal and tumour
cells from the oxidative damage [106]. In this context,
some studies highlight the adverse effects of antioxidant
supplementation on overall mortality for patients with cancer
[388, 389]. However, other studies proved the benefits of
antioxidant supplementation in a specific treatment (e.g.,
chemotherapy [112]; radiotherapy [390]; and both [381]).
Based on these restricted outcomes of the observational
studies and clinical trials, there does not appear to be obvious
evidence concerning the effect of antioxidant supplemen-
tation and its use during chemo and radiation treatments.
Therefore, high-quality placebo-controlled trials are needed.
4.2.1. Vitamin A and Carotenoids. Vitamin A refers to a
group of compounds named retinoids which cooperate in
a large variety of physiological processes such as in vision,
bone growth, reproduction, cell division, and differentiation
[391, 392]. Two forms of vitamin A can be ingested via diet:
preformed vitamin A, found in foods derived from animal
sources (e.g., liver, whole milk) and absorbed as retinol, and
provitaminA carotenoids, derived from fruits and green leafy
vegetables and converted into retinol once ingested. Most of
the supplements contain the preformed vitamin A [391]. It is
stored in the liver. Synthetic retinoids are also available such
as bexarotene and fenretinide.
Various longitudinal cohort studies, performed in dif-
ferent ethnical groups and geographic locations worldwide,
evaluated the intake of carotenoid and endogenous retinol
levels with the risk for developing breast cancer [115–118].The
type of beneficial carotenoids is controversial [115–121]. For
example, in the postmenopausal women population, some
studies did not correlate the retinol levels with breast cancer
risk [115, 117]. Other studies demonstrated different effects
between the lycopene levels (i.e., a carotenoid substance that
does not convert into vitaminA) and the risk of breast cancer,
that is, an increased risk [116, 119] or a protective effect among
ER-positive and progesterone receptor-positive breast cancer
[120].
The European Prospective Investigation into Cancer and
Nutrition cohort studied 1502 female incident breast cancer
cases (premenopausal (𝑛 = 582) and oestrogen receptor-
negative cases (𝑛 = 462)). Carotenoids, tocopherols, vitamin
C, and retinol plasma levels were determined to find an
association with risk of breast cancer.The results showed that
a higher concentration of plasma 𝛽-carotene and 𝛼-carotene
is associated with lower breast cancer risk of oestrogen
receptor-negative tumours and higher risk of breast cancer
was found for retinol in relation to oestrogen receptor-
negative/progesterone receptor-negative tumours. There was
no statistical difference for the other studied compounds
[121].
A positive relationship between a high plasma caroten-
oids and breast cancer survivals was reported by Rock et al.
in the Women’s Healthy Eating and Living study [122].
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Higher biological exposure to carotenoids, when assessed
over the period of the study, was associated with greater
likelihood of breast cancer-free survival regardless of study
group assignment.
4.2.2. Vitamin C. Vitamin C, or ascorbic acid, is an essen-
tial water-soluble vitamin that acts as antioxidant and has
important biological roles such as in protein metabolism,
including the biosynthesis of collagen, neurotransmitters,
and L-carnitine; in immune function and in absorption of
iron from plant-derived foods [391]. This vitamin, which is
crucial for the structural integrity of intercellular matrix, is
produced by the most animals but not by humans who must
get it from the diet or as supplement.
There is restricted evidence of using vitamin C supple-
mentation in the primary prevention or delay of total cancer
incidence, including breast cancer [115, 393]. One of the
largest studies in women, followed up for 9.4 years, reported
that the supplementation with 500 mg daily of vitamin C had
no effect on the occurrence of breast cancer [393]. However,
in a cohort study including postmenopausal women, Cui and
colleagues found a significant increased risk of breast cancer
with high dose of vitamin C supplementation [120].
The safety of oral vitamin C supplements subsequent
of the cancer diagnosis is not obvious [386]. The attention
given to vitamin C is increasing since the publication of
the in vitro study by Chen and collaborators [394] which
verified the selective apoptosis of cancer cells induced by high
concentrations of vitamin C. This effect was also supported
by Ullah et al. [395]. Additionally, vitamin C enhances
immunity and presents antioxidant properties including the
neutralization of free radicals which may interfere with
cancer progression [396]. The important issue is if these
beneficial outcomes can be effective in vivo (i.e., in human
body) considering the solubility of this vitamin and some
parameters should be clarified, namely, the dose of vitamin
C, the timing of supplementation, the side effects of high
concentration of vitamin C (e.g., for kidneys), and its effect in
combination with pharmacological and conventional cancer
therapies (e.g., chemo- and radiotherapy). These properties
are controversial and seem to be dependent on the dose,
the source of vitamin C intake (i.e., derived from food or
supplementation), and the timing and duration of intake
[125, 397]. For example, some studies associated the dietary
vitamin C intake with reduced risk of breast cancer mortality
[125, 398] and no relationship demonstrated in other studies
[26]. Additionally, the results also varied in the case of
vitamin C supplementation. Studies reported inverse asso-
ciation between vitamin C supplementation, most of them
referred to postdiagnosis breast cancer supplementation and
mortality or recurrence [123, 126, 381], and no associationwas
reported by Harris et al. [125]; however, this study presented
a limited power analysis. These differences are probably
related to the limitations of each study (i.e., small population
with no confidence intervals or statistical analysis; details of
concurrent treatment, heterogeneity across included studies).
The relationship between vitamin C supplement intake and
breast cancer risk was evaluated in an epidemiologic study
with 57,403 postmenopausal women via food-frequency and
supplement questionnaires. Vitamin C supplement was not
associated with breast cancer risk overall but was associated
with increased postmenopausal breast cancer risk in women
with high vitamin C intake from foods [124].
Concerning the use of antioxidant supplements, includ-
ing vitamin C, during conventional treatment of cancer, the
evidence from experimental studies and observational or
clinical trials is also controversial. Jacobs et al., since there is
no high-quality evidence to confirm the benefits of vitamin
supplementation in cancer patients (either increases the
antitumour effects of chemotherapy or reduces its toxicity),
do not recommend the use of this vitamin until double-blind
placebo-controlled trials are completed [399]. Moreover,
Subramani and collaborators verified that the pretreatment
of MCF-7 breast cancer cells with vitamin C, in a dose-
dependent reply, protected them against lipid peroxidation
caused by tamoxifen treatment [400]. However, Hubner and
Hanf suggested that the vitamin C from dietary sources
does not have negative effects not only in chemo- and
radiotherapy but also for targeted drugs [397]. Vitamin C
(500mg daily) supplementation in combinationwith vitamin
E (400mg daily) and tamoxifen therapy, for the period of
3 months, in postmenopausal women with breast cancer
reduced the tamoxifen effect in plasma lipid and lipoprotein
levels [127].The tamoxifen therapymay enhance the synthesis
of VLDL and diminish the activity of lipoprotein lipase which
hydrolyses triglycerides [391]. A retrospective study showed
fewer side effects of chemotherapy in breast cancer patients
supplemented with low-dose infusion of vitamin C [401];
nonetheless this study did not refer to recurrence and survival
data and conclusions about its safety could not be assessed.
In a randomized 5-month study, Suhail and collaborators
concluded that the supplementation of vitamin C (500mg
daily) and vitamin E (400mg daily) restores antioxidant
status, lowered by the breast cancer and chemotherapy, and
reduces the DNA damage [128]. The authors also suggested
that this regimen of supplementation should be helpful in
protecting against the side effects associated with the cycles
of chemotherapy treatments. Other studies reported similar
conclusions after intravenous vitamin C administration [129,
130]. For example, Vollbracht et al. conducted a retrospective,
multicentre, epidemiological cohort study which proved that
the intravenous vitamin C administration improves quality
of life in breast cancer patients during chemo/radiotherapy
and aftercare [130]. In this context, the route (oral versus
intravenous) used for vitamin C supplementation should also
be considered when evaluating the efficacy and safety among
cancer patients. Pharmacokinetic studies suggest that much
higher levels of plasmatic vitamin C can be achieved by
bypassing the oral route [402].
The dose of vitamin C supplementation varied in the
breast cancer patients from 400mg or less per day (in the
Shanghai Breast Cancer Survival Study [381]) to higher than
1 g [403]. Development validated randomized trials are war-
ranted to define if these higher amounts are safe and which
dosage is required to reach the experimental concentrations
described by Chen et al. [394]. Different levels of intake
(from both dietary and supplementation) may influence the
safety and efficacy in cancer patients [386]. Hoffer et al., in
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a dose-finding phase I study, demonstrated that the intra-
venous administration of ascorbic acid in a low-dose had
inferior outcomes compared to patients supplemented with
higher doses [404].
Ascorbic acid is a critical nutrient for the synthesis and
integrity of collagen and for the optimal stability of the extra-
cellularmatrix which are essential factors for controlling can-
cer. Based on the presumption that cancer patients have low
reserves of ascorbic acid [405], Cha and colleagues showed
that the supplementation of ascorbate in ascorbate-restricted
mice injectedwith breast cancer cells reduced tumour growth
and enhanced encapsulation of tumours [406]. Additionally,
it modulated inflammatory cytokine secretion. These results
support the proposed approach of using vitaminC to treat the
cancer [407]. The administration of intratumoural vitamin C
delayed tumour growth in murine solid tumour models and
synergistic antitumour effects were observed with cisplatin
[408]. However, this study was performed on animals. So, the
use of vitamin C as anticancer therapy is not recommended
in cancer patients.
4.2.3. Vitamin E. Vitamin E is a liposoluble vitamin that
exhibits different pharmacological properties such as antiox-
idant, anti-inflammatory, and inhibition of protein kinase C
[391]. It can be acquired from some dietary sources (e.g.,
nuts, seeds, vegetal oils, green leafy vegetables, and fortified
cereals) or as a supplement. Among its different chemical
forms, the alpha-tocopherol is themain andmost active form
achieved in human plasma and studied in clinical trials.
The supplementation with vitamin E in breast cancer
patients has also different outcomes. Some of the effects of
vitamin E in breast cancer have been explored previously
with the coadministration of other antioxidant vitamins (e.g.,
vitamin C). Other studies have shown that long-term uptake
of vitamin E could have a negative effect on breast cancer
patients [114, 131]. The HOPE-TOO trial revealed no effects
of long-term vitamin E supplementation (7.1 years) on indi-
vidual rates of breast cancer [409]. Nagel and collaborators
did not find any association between long-termdietary intake
vitamin E (8.8 years) and risk of breast cancer development
[109]. Alpha-tocopherol acetate (400mg) supplementation
increased biomarkers of estrogen-stimulation in 5 out of 7
breast cancer patients while taking tamoxifen suggesting that
vitamin E supplements may decrease the antiproliferative
effect of tamoxifen [132].
Tam et al. verified that alpha-tocopheryl succinate, a
synthetic derivative of alpha-tocopherol, improved the cells’
sensitivity to doxorubicin (anticancer agent) which reduced
the cell viability in cancerous breast tissue samples [410].
This combination, using vitamin E or its analogue in a
supplementation regimen, is promising for the treatment of
cancer. Random placebo-controlled trials showed that the
association of pentoxifylline and vitamin E after radiotherapy
in breast cancer women may be used to prevent radiation-
induced side effects [133, 134].
In another study, the intracardiac injection of Trolox
inhibited osteolysis bone metastasis caused by breast cancer
in an experimental metastasis model [411]. Despite this,
vitamin E analogue did not have any effect in the mammary
fat pad model; it suppressed breast cancer cell-induced
osteoclast differentiation and the invasive behaviour of cancer
cells via prostaglandin E2- (PGE2-) dependent and PGE2-
independent mechanisms.
4.2.4. Selenium. Selenium is an antioxidant mineral that
activates enzymes (e.g., glutathione peroxidase)which partic-
ipate in themetabolismof oxidants and drugs [412].However,
this activation is dependent on the physiological selenium
concentrations which should be between 70 and 90mcg/L
[413]. In humans, physiological selenium concentrations
depend on the intake of food products containing high
levels of selenium (e.g., grains, cereals, organ meats, and
seafood, with lower amounts in dairy products, fruits, and
vegetables), the selenium content in soil of each geographic
region, and the supplementation [397]. However different
organic nutritional forms of selenium are available for cancer
prevention; sodium selenite is the favourite form of selenium
for therapeutic purposes [414].
Selenium appears to be a crucial trace element recognized
in some types of cancers as cancer-protective agent [415].
Adequate selenium levels should be maintained to provide
therapeutic benefits such as preventive activity in breast
cancer [416]. In a meta-analysis, prospective studies demon-
strated the protective effect in cancer incidence when patients
were supplemented with selenium in the case of deficiency
in physiological levels [417]. Nevertheless, the results from
studies are again unclear. In another meta-analysis study, the
authors evaluated the association between selenium expo-
sure/supplement and cancer risk and did not find a protective
efficacy of selenium supplement [418]. Additionally, different
effects (i.e., decreased or not associated effect) on specific
types of cancer were reported; namely, it decreased the risk
of breast cancer. In a review paper related to the prevention
of cancer by selenium, the authors reported that positive
evidence was only achieved from epidemiological data and
not from randomized studies [415]. From this perspective,
before the supplementation of cancer patients with selenium
(e.g., sodium selenite), the individual selenium status should
be measured (e.g., selenium in whole blood) [419] to avoid
overdosing and side effects such as higher incidence of serum
lipids, hypertension, and diabetes [391].
To investigate the input of selenium and other trace
elements in the etiology of breast cancer, Adeoti and collabo-
rators determined the serum concentration of these elements
in breast cancer patients [420]. An inverse relationship
between the concentration of zinc and selenium in the venous
blood was verified while that of the control reported a
direct relationship.The authors demonstrated the association
between the serumconcentration of trace elements, including
selenium, and breast cancer.
In addition, selenium seems to reduce the side effects of
radiotherapy and does not affect the efficacy of conventional
treatments [421]. In this study, diarrhoea was significantly
reduced in the group supplemented with selenium.
4.2.5. Vitamin D and Calcium. Vitamin D is a liposoluble
vitamin mainly acquired through endogenous synthesis via
sun exposure of the skin (ultraviolet B rays); a daily sunlight
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exposure can generate the equivalent of a 10,000 IU oral
dose of vitamin D3 [188]. It can also be obtained from
dietary sources (e.g., fatty fish and fortified food products,
cereal, milk and dairy products, beef, and liver) or as a
nutritional supplement (ergocalciferol (D2) or cholecalciferol
(D3)) [422]. Either of these forms needs to be metabolized
via hydroxylation in the liver and kidney to the active form
known as calcitriol. Our levels of vitamin D are mainly
affected by the limited sun exposure (darker skin, use of
sunscreen, season, latitude, and time of day) and limited
physical activity. However, daily recommended intake (DRI)
values generally consider vitamin D levels in persons with
limited sun exposure as adequate to restore levels. Several
other biological systems (e.g., heart, brain, muscle, immune,
pancreas, and control cell cycle) present vitamin D receptors.
Physiologically, appropriate levels of vitamin D are essential
in skeletalmineralization, regulation of parathyroid hormone
production, and maintenance of calcium and phospho-
rous plasmatic concentrations [423]. Vitamin D regulates
intestinal calcium absorption and bone and renal calcium
resorption [422]. Regarding the topic of cancer, it presents
promising actions [424]: regulating the expression of genes
that are involved in development and progression of cancer;
being able to stimulate cell differentiation and apoptosis;
inhibiting proliferation, angiogenesis, invasion, inflamma-
tion, andmetastatic potential; suppressing aromatase activity
leading to reduce estrogen levels and reduced breast cancer
risk. Blood levels of 25-hydroxy-vitamin D can be measured
to determine a deficiency of vitamin D [423].
Vitamin D deficiency is common among cancer patients,
namely, in breast cancer cases [135, 154, 160, 167, 170, 425].
Some authors found no association between breast cancer
risk and vitamin D/calcium intake [136, 138–140, 142] or
serum levels [145–147]. Studies about intake or serumvitamin
D and/or calcium levels found controversial results: dietary
vitamin D or serum levels were associated with a decrease
of breast cancer risk in several countries such as Pakistan
[154], Iran [161], Korea [162], USA [163, 164], Europe [165],
Australia [156], France [150], Italy [153], and Germany [166];
dietary calcium and vitaminD had no association with breast
cancer risk in a large cohort study performed in Europe
[141] but other authors found a significant evidence of the
inverse relationship between vitamin D and calcium intake
and breast cancer risk, related or not to menopausal status
[157, 158], a U-shape association between plasma vitamin
D levels and breast cancer risk while an inverse association
was observed with serum calcium levels [171–173]. Serum
calcium levels were inversely associated with breast cancer
in premenopausal women and the opposite occurred in
overweight postmenopausal women [169]. However, in Asian
population calcium serum levels and breast cancer were not
related [148]. The risk of breast cancer also appears to vary
with menopausal status. While no relation between vitamin
D serum levels was found in premenopausal women, an
inverse association seems to be evident in postmenopause
with threshold serumvalues of 27 ng/ml [168]. Lee et al. found
that vitamin D has a protective effect on premenopausal
women [155]. Despite the fact that age may be a risk factor,
Mohr et al. showed no relationship between vitamin D levels
and breast cancer in young military women [137], and results
in postmenopausal women revealed no association either
[136, 145]. Until now there is no agreement about the optimal
dietary vitamin D and calcium intake to diminish breast
cancer risk. However, based in existing studies, some authors
suggested that daily intake of 600 mg calcium + 400 IU
vitamin D and a target of 30–50 ng/ml of serum vitamin
D may achieve the lowest risk of breast cancer in women
[153, 166, 426].
Discordant data about the dietary source of those nutri-
ents have been also discussed. Dietary but not vitamin D
supplement was positively associated with increased breast
cancer risk [176]. Other studies found no association with
dairy products consume and breast cancer risk [149, 151,
427]. Sun exposure is also a relevant source of vitamin
D and it seems to be an important protective factor
when combined with dietary vitamin D, especially in post-
menopausal women at northern latitudes with poor UV light
[152].
Nonetheless, there are no adequate clinical trials that
support the promising outcomes of supplementation breast
cancer patients, in the case of a shortfall, with vitaminD.Most
of the studies referred to the fact that the results required
cautious interpretations. In accordance with Goodwin et al.
[181], vitamin D deficiency in these patients is a negative
prognostic factor. Women with aggressive subtypes of breast
cancer have lower serum vitamin D levels which can be an
indicator of poor prognostic [177, 183, 184]. For example, in
a multiethnic cohort, Villasen˜or and collaborators revealed
that higher serumof 25-hydroxy vitaminDmay be associated
with improved survival, but the results were not statistically
significant, referring to the need of including additional
endpoints in future larger studies [182]. Calcium serum levels
were positively related to breast cancer aggressiveness in
premenopausal womenwith orwithout overweight [185].The
calcium/magnesium ratio appears to be also important since
they have antagonist effects on absorption-resorption cycle.
Magnesium intake has been related to an improved breast
cancer survival and this effect is potentiated with higher
calcium/magnesium ratios [180].
Vitamin D intake was not related to breast cancer recur-
rence independently of menopausal status [179].
Some studies related the lower risk of breast cancer and
vitamin D to the inhibition of cell proliferation via nuclear
vitamin D receptor (VDR). Polymorphism of VDR may be
determinant in the breast cancer risk andmay also explain the
controversial data from different epidemiologic studies [176,
178, 428]. However, despite contradictory results reported in
different studies, polymorphism of this receptor has been
pointed as responsible for individual sensitivity to vitamin D
[174, 429]. This relation might be also dependent on breast
cancer subtype and menopausal status [175].
As with other nutritional supplements, in vitro and in
vivo studies using vitaminD in breast cancer patients demon-
strated contradictory results. Because a high concentration
of calcitriol induces the hormone transcriptional targets
and presents antiproliferative effects in culture breast cancer
lineages, Urata et al. evaluated the outcomes of calcitriol
supplementation in postmenopausal breast cancer specimens
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[430]. However, the authors could not extrapolate the effects
observed in vitro to in vivo analyses.
In this context, a universal benefit from vitamin D
supplementation among patients with cancer will be influ-
enced by various factors, including the baseline vitamin
D status, vitamin D receptor polymorphisms, and variable
target effects dependent on the vitamin D receptor status of
the tumour [383].
Many breast cancer patients have different risk factors
for the development of osteoporosis such as age or aro-
matase inhibitor therapy. The use of aromatase inhibitor in
postmenopausal women can generate a harmful effect on
bone mass and an augmentation in fracture risks. These
musculoskeletal symptoms appear probably due to estrogen
deficiency caused by aromatase inhibitor [431]. Vitamin D is
a promising and effective approach to reduce the incidence
and severity of arthralgia resulting from aromatase inhibitor
treatment [186, 190, 191, 193]. Sometimes, even with the
supplementation of 500–1.000UIwomen present a vitaminD
deficit [186, 431]. Khan et al. [190] successfully supplemented
patients with high doses of vitamin D (50,000 IU per week)
for several weeks to control joint pain and fatigue associated
with letrozole (i.e., an aromatase inhibitor). Other authors
achieve similar improvement with calcium and/or vitamin D
supplementation [187, 192, 432].
Amir and colleagues [188] explored the effects of high
dose vitamin D3 (10,000 IU/day for 4 months) in breast
cancer patients with bonemetastases. In this phase 2 trial, the
authors suggested the safety of supplementation but neither
significant palliative benefit nor significant change in bone
resorption occurred.
In breast cancer patients, whose bone density can be
affected by chemotherapy-induce menopause and aromatase
inhibitor, clinical practices guidelines recommend the sup-
plementation not only with vitamin D but also with calcium
[189]. Calcium is the most prevalent mineral in the body.
Chung et al. reported no benefits for bone density or risk
of fractures in breast cancer patients supplemented only
with vitamin D and limited benefits for combination higher
doses of vitamin D (>10 𝜇g/day) with calcium (>1,000mg) in
noninstitutionalized individuals [433]. In a systematic review,
results from trials point to insufficient calcium and vitamin
D supplementation doses (i.e., 500–1500mg for calcium and
200–1000 IU vitamin D) to prevent bone mineral density loss
[189]. Vitamin D supplementation was associated with an
improvement in bone loss if target serum levels of 30 ng/ml
were achieved [194], but some negative results are also
reported. Doses of 500–1500mg calcium and 200–1000 IU
vitamin D were not sufficient to prevent bone mineral
loss [189]. Some of the studies reported associated calcium
supplementation with the enhanced risk of cardiovascular
disease, so future validated trials should be considered to
evaluate the safety and efficacy of these regimens of sup-
plementation in women undergoing breast cancer therapy.
Another aspect to consider is the confounding factor in
human trials. Deschasaux et al. found that body mass index
and alcohol consumptionmaymodify the effect of vitamin D
on breast cancer risk, which can be the reason for discrepant
results between studies [159].
There are very few randomized placebo-controlled trials
that proved the efficacy, safety, and optimum dosage of
vitamin D and calcium supplementation for cancer patients.
Rohan et al. found no benefit in the administration of daily
use of 1000mg of calcium carbonate and 400 IU of vitamin
D3 for 7 years, in postmenopausal women and the risk of
benign proliferative breast disease [143]. The same study
concluded that daily doses used were not associated with a
protective effect related to breast cancer risk [144].
Vitamin D deficiency has also been linked with increased
toxicity from bisphosphonate therapy, which can provoke
hypocalcaemia [434]. Currently, researchers investigate the
need to supplement vitamin D and calcium simultane-
ously with bisphosphonate therapy [435]. In a double-blind,
randomized, placebo-controlled study, Rhee et al. proved
the efficacy of combined alendronate (5mg) and calcitriol
(0.5 𝜇g) to prevent bone loss due to aromatase inhibitor in
Korean postmenopausal women with early breast cancer.
Despite the huge data from experimental and observa-
tional studies, a better understanding of the biologic effect of
vitamin D in breast tissue and a more careful clinical design
will be useful for making recommendations for vitamin D
supplementation among breast cancer prevention or treat-
ment.
4.2.6. B Complex Vitamins. B complex vitamins include eight
water-soluble vitamins: vitamin B1 (thiamine), vitamin B2
(riboflavin), vitamin B3 (niacin or niacinamide), vitamin
B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7
(biotin), vitamin B9 (folic acid), and vitamin B12 (cobalamins;
cyanocobalamin) [391]. Each B complex vitamin presents a
specific function in the human organs. Some of them can
be found naturally in unprocessed food (e.g., beans, meat,
poultry, fish, eggs, milk, peas, select fruits, and vegetables)
or fortified products (e.g., fortified cereals). Additionally,
supplementation with complex B vitamins is also considered
as an approach in the case of breast cancer patients or
survivors, namely, folic acid [436]. These authors concluded
that folic acid supplementation may promote the progression
of established breast tumours.
Different conclusions were also reported in the literature
related to the effect of B complex vitamins and the risk
for breast cancer development [195–199, 201–203, 205–218,
437]. In different clinical studies, despite the fact that several
authors verified that some vitamins of B complex (e.g.,
folate, vitamin B6, and vitamin B12) did not reduced the
risk of developing breast cancer [202, 216, 437] even when
stratified by hormone receptor status, other ones reported an
association [195, 199, 208–213, 217]. For example, using data
from the European Prospective Investigation into Cancer and
Nutrition (EPIC), that is, a large prospective cohort study
including 23 centres in 10 European countries [203], the
plasma folate and vitamin B12 levels were not associated with
the risk of breast cancer or by hormone receptor status [437].
Kim and colleagues indicated that high folate plasma concen-
trations may be associated with increased breast cancer risk
among women with a BRCA1/2 mutation (i.e., tumour sup-
pressor genes) [195]. In contrast with these results, a higher
dietary folate intake may diminish breast cancer risk and
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this association may differ by menopausal and sex hormone
receptor status [213, 214]. In another based EPIC cohort study,
themain conclusions were as follows: high vitamin B6 plasma
concentrationsmay reduce the breast cancer risk, particularly
of estrogen receptor (+) breast cancer; high riboflavin plasma
levelsmay reduce the breast cancer risk in premenopausal but
not in postmenopausal women; and homocysteine and the
other B vitamins do not seem to influence breast cancer risk
[218]. In a large randomized, controlled trials, combined B
vitamins daily supplementation (vitamin B6, 50mg; vitamin
B12, 1mg; folate, 2.5mg), administrated over a period of
7.3 years, had no significant effect on the cancer breast risk
[196]. In different meta-analysis studies concerning folate
plasmatic levels or folate (fromdiet and/or supplementation),
the authors reported no association between folate intake
and risk for developing breast cancer [215], and this did
not vary by menopausal status or hormonal receptor status
[197, 198]. In addition, some of these studies suggested
that adequate ingestion of folate may have protective effects
against breast cancer risk in women with moderate to high
alcohol consumption level [215]. Zhang et al. also achieved
similar conclusions; that is, folate intake had little or no
effect on the risk of breast cancer; moreover, a dose-response
meta-analysis suggested an association between folate intake
and breast cancer risk; daily folate intake of 200–320 𝜇g
appeared to associate with a lower risk and a daily folate
intake >400 𝜇g/d with an increased risk [205]. In a systematic
review of clinical studies, Castillo and collaborators suggest a
caution in women exposed to high folate intake during the
folic acid fortification era, once some studies demonstrated a
higher risk of this population for development breast cancer
[201]. A weak relationship between the dietary vitamin B2
intake and the reduction of breast cancer risk was also shown
in another systematic review and meta-analysis study [207].
Some vitamins of the B complex can interact with
one-carbon metabolizing genes which can have an impor-
tant role in the breast cancer development [219–224]. For
example, some case-control studies assessed the association
between MTHFR (5,10-methylenetetrahydrofolate reduc-
tase) and MTR (methionine synthase) genotypes and breast
cancer risk [219–224]. These enzymes are involved in the
metabolism of folate and homocysteine and their deficiencies
could explain some alterations during breast carcinogenesis.
The results proved that some MTHFR (e.g., C667T and
2756GG genotypes) and MTR polymorphisms (e.g., 2756GG
genotype) are associated with risk of development breast
cancer in different populations [219, 221–224]. Despite the
fact that several studies reported an influence of dietary
specific B complex vitamins (e.g., folate, vitamin B6, and
vitamin B12) intakes on these associations [221–224], some
authors stated no association [219, 220, 223, 224]. Dietary
methyl group donors such as some B complex vitamins
could influence the hypermethylation status of certain genes.
Pirouzpanah and colleagues showed that individual B vita-
mins can present different effects on promoter hypermethy-
lation and methylation-related expression of retinoic acid
receptor-beta (RARB) and breast cancer-1 (BRCA1) genes in
Iranian patients with breast cancer [225]. Hypermethylation
at promoters of RARB and BRCA1 is associated with reduced
transcript levels of the respective gene in primary breast
cancer tissue samples.
The folate also plays an important role in the regenerating
methionine, the methyl donor for methylation, and in the
DNA synthesis and repair and, consequently, in carcinogene-
sis process [438]. In a case-control study involving patients at
a tertiary hospital in Uganda, the red blood cell folate levels
were not associated with breast cancer risk [204].
Concerning the influence of folate in survival, a prospec-
tive cohort study reported that folate supplementation is
unlikely to have a significant adverse effect on breast cancer
survival among women treated with chemotherapy [200]. In
another case-control study, the authors verified that higher
dietary vitamins B1 and B3 intake as well as specific polymor-
phisms of one-carbon metabolizing genes were associated
with improved breast cancer survival [226].
Some chemotherapy often originates cutaneous side
effects, namely, dry, itchy, and irritable skin due to nonspe-
cific inhibition of the proliferative activity of keratinocytes.
Based on the skin barrier stabilizing effect of vitamin B3
(niacinamide), Wohlrab et al. [227] conducted a multicentre
prospective randomized reference-controlled crossover study
and proved the superiority of topical preparation containing
niacinamide compared to standard care.The authors demon-
strated the cytoprotective and barrier stabilizing effect of
vitaminB3 and its prophylactic application for controlling the
cutaneous symptoms andmaintaining quality of life in breast
cancer patients while undergoing cytostatic therapy.
4.3. Omega 3 Polyunsaturated Fatty Acids (PUFA). Eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA) are
long-chain (𝑛-3) polyunsaturated and highly peroxidizable
fatty acids which are obtained mainly from marine sources.
These supplements have important anti-inflammatory prop-
erties. Based on the results of preclinical and clinical studies,
supplementationwith omega 3PUFA seems to be a promising
approach among breast cancer patients. Food sources may
be used with similar results [228]. Due to their nature, safety
should not be a critical issue.
In a long-term prospective study, Brasky et al. showed
an inverse association between the supplementation with
omega-3 fatty acid and breast cancer risk [235]. This asso-
ciation depends on the type of fatty acids. For example,
Pouchieu and colleagues [229] proved that specific plasma
saturated, monounsaturated, and polyunsaturated fatty acids
were differently associated with breast cancer risk. These
authors reported that the total PUFAs were correlated with
breast cancer risk only in the placebo group. Additionally, a
modulation role of antioxidant agents in these associations
via neutralizing the potential effects of these fatty acids on
carcinogenesis was also suggested.
Different meta-analysis of epidemiological studies sug-
gested that fish consumption and dietary fatty acids might
be not associated with breast cancer risk [231–234]. Some
authors proposed conducting well-designed prospective
studies to explore the role of fish consumption/dietary fatty
acids in relation to breast cancer risk [233]. However, Zheng
et al. found an inverse relationship between dietary marine
𝑛-3 PUFA and breast cancer risk. The increment of dietary
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𝑛-3 PUFA of 0,1 g/day may reduce breast cancer risk in 5%
[238]. So, dietary oil fish intake or supplementation had a
protective effect in breast cancer patients [236]. More pro-
nounced preventive effects were found between omega 3 and
postmenopausal women at risk [236, 237]. The populations
who consume high levels of omega 3 and low levels of
omega 6 showed a breast cancer risk reduction. In contrast
to omega 3, omega 6 induces inflammation reactions [241].
In a meta-analysis, Yang et al. also demonstrated the negative
association between the higher omega 3: omega 6 ratio intake
and breast cancer risk [239]. Similar results were achieved by
Murff and collaborators [240].
The protective effect of omega-3 fatty acids was putted
to the test in a pilot study of 35 postmenopausal women
with cytological evidence of hyperplasia, with an intake of
1860mg EPA + 1500mg DHA ethyl esters daily for 6 months.
A favourable decrease in several breast cancer biomarkers has
indicated the need of further placebo-controlled clinical trials
[243].
Patterson and collaborators did not associate EPA and
DHA intake from fish oil supplements with breast cancer
outcomes [230]. Sandhu et al. found an increased effect of
protective omega-3 fatty acid supplementation in higher body
mass index women [244].
To determine the dose of omega-3 fatty acids that reach
the maximal target tissue effects in women at high risk of
breast cancer, Yee et al. [242] suggested that doses up to 7.56 g
of DHA and EPA (per day) were well tolerated with optimal
compliance. A combination of omega 3 (4 g) and ralox-
ifene (30mg)—a breast cancer chemopreventive agent)—was
successful in reduction insulin-like growth factor (IGF-1)
levels and omega 3 added the additional effects of improving
serum lipids, antioxidant, and anti-inflammatory activities
[245, 246].
EPA and DHA can increase the production of ROS in
cancer cells, so they are being investigated as promising adju-
vants of cancer treatment (e.g., chemotherapy; radiotherapy)
to maximize the sensitivity of residual tumour cells to the
therapy and maintain or (preferably) decrease the sensitivity
on nontumour cells without any additional side effects [383,
439]. A phase II trial has proved the safety and feasibility
benefits of omega 3 PUFA when supplemented together
with chemotherapy. Bougnoux et al. [247] supplemented
with DHA (1.8 g/day) metastatic breast cancer patients that
were receiving anthracycline-based chemotherapy. Despite
the limited number of patients (i.e., 𝑛 = 25), the authors
reported an increase disease-free survival and a longer time
to progression in patients with high DHA incorporation into
plasma phospholipids.
Considering the effects of EPA and DHA on cellular
processes of bone turnover, these fatty oils may compensate
aromatase inhibitors effects to bone and seems to be a
promising approach in this clinical situation. Hutchins-Wiese
et al. [248] supplemented postmenopausal breast cancer
survivors with aromatase inhibitors with a high dose of DHA
and EPA (4 g/daily for 3 months) and demonstrated that
PUFA supplements can reduce bone resorption. Considering
the short-term effects of fish oil supplementation, long-term
studies are required.
5. Conclusions and Perspectives
Breast cancer is one of themost leading causes of cancer death
among women. Women with a breast cancer history often
resort to alternative and complementary therapies, mainly
phytotherapeutic products and nutritional supplements, for
the management of the typical symptoms and adverse effects
of conventional cancer treatments. Although extensively
used, these products are poorly regulated and can have either
positive (e.g., synergetic effects) or negative (e.g., metabolic
and drug interactions, diminishing the therapeutic benefits
of conventional cancer treatments). There is a lack of high-
quality scientific evidence for many of the most phytother-
apeutic products and nutritional supplements and more
clinical scientific evidences concerning the safety and efficacy
are mandatory. Additionally, pharmacovigilance practices
for these natural products are crucial to understanding the
benefit, limitations, dosage regimen, and potential effects
and how these modalities need to be modified during some
periods.
Tables 1 and 2 summarize themain effects in the consulted
clinical studies. Clinical studies were gathered accordingly
to disease phase and main action. The ratio of trials versus
nontrials included all the interventional clinical trials versus
total of clinical studies.
Based on clinical study data, the following supplements
can be used in the different phases of breast cancer history:
(i) Preventive Effects
Phytotherapeutic products: flaxseed; green tea.
Nutritional supplements: omega 3 polyunsaturated
fatty acids (minimum daily dose of 2.5 g in women at
high breast cancer risk).
(ii) During Conventional Treatments after Diagnosis
Phytotherapeutic products: U. tomentosa as an adju-
vant treatment of FAC (Fluorouracil, Doxorubicin,
and Cyclophosphamide) regimen in Invasive Ductal
Carcinoma Stage II; Curcuma longa as coadjuvant in
docetaxel therapy; green tea as adjuvant of radiother-
apy; Viscum album in side effects, recurrence, and
antitumour activity.
Nutritional supplements: vitaminC 500mg+ vitamin
E 400mg in side effects chemotherapy, vitamin D
(necessary doses to target 30–50 ng/ml serum levels)
+ calcium, and vitamin D as adjuvant of aromatase
inhibitor therapy; DHA as adjuvant in chemotherapy
and side effects.
(iii) Posttreatment (i.e., Survival Period)
Phytotherapeutic products: Salvia sp. associated with
Coriolus versicolor improves immunologic function.
Based on the current literature we concluded that well-
designed clinical studies are needed to obtain high level of
evidence to accomplish recommendation guidelines.
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